Compare BIT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIT | PHAR |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 678.5M | 793.4M |
| IPO Year | 2012 | 2020 |
| Metric | BIT | PHAR |
|---|---|---|
| Price | $11.18 | $9.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.35 |
| AVG Volume (30 Days) | ★ 509.1K | 35.4K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.92 |
| Revenue Next Year | N/A | $8.85 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.10 | $9.62 |
| 52 Week High | $13.46 | $21.34 |
| Indicator | BIT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 27.25 | 34.07 |
| Support Level | $11.10 | $9.62 |
| Resistance Level | $12.64 | $11.60 |
| Average True Range (ATR) | 0.14 | 0.40 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 11.40 | 1.93 |
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loans and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.